Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
Phase 1 Completed
29 enrolled
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Phase 1 Completed
Stereotactic Radiosurgery in Treating Patients With Brain Tumors
Phase 1 Completed
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase 2 Completed
137 enrolled 13 charts
Natural History of Patients With Brain and Spinal Cord Tumors
Completed
3,050 enrolled
AZD8055 for Adults With Recurrent Gliomas
Phase 1 Completed
22 enrolled
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
Phase 2 Completed
30 enrolled 19 charts
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 1/2 Completed
116 enrolled 17 charts
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase 2 Completed
97 enrolled 35 charts
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Phase 1/2 Completed
136 enrolled 27 charts
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
Phase 1/2 Completed
50 enrolled 6 charts
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
Phase 2 Completed
112 enrolled 12 charts
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Phase 1 Completed
55 enrolled
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
Phase 2 Completed
31 enrolled 6 charts
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
Phase 2 Completed
42 enrolled 11 charts
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Phase 1 Completed
22 enrolled
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
Phase 2 Completed
30 enrolled 8 charts
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
Phase 1/2 Completed
69 enrolled 12 charts
CC-5013 in Treating Patients With Recurrent Glioma
Phase 1 Completed
CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas
Phase 1 Completed
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
Phase 1 Completed
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
20 enrolled
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
Phase 1 Completed
31 enrolled
Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
Phase 1 Completed
47 enrolled
Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
Phase 1 Completed
61 enrolled
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
Phase 1/2 Completed
52 enrolled 17 charts
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Phase 2 Completed
11 enrolled 7 charts
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
Phase 1 Completed
72 enrolled
Cilengitide in Treating Children With Refractory Primary Brain Tumors
Phase 1 Completed
24 enrolled
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
Phase 1 Completed
45 enrolled
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Phase 1 Completed
20 enrolled
Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma
Phase 1 Completed
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
Phase 1/2 Completed
Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors
Phase 1/2 Completed
Pharmacologic Study of Methotrexate in Patients Undergoing Stereotactic Biopsy for Recurrent High-Grade Glioma
Phase NA Completed
12 enrolled
Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors
Phase 2 Completed
Procarbazine in Treating Patients With Recurrent Brain Tumor
Phase 1/2 Completed
COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors
Phase 1/2 Completed
Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase 1/2 Completed
48 enrolled
Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma
Phase 2 Completed
60 enrolled
Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma
Phase 1 Completed
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
Phase 1 Completed
36 enrolled
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
Phase 2 Completed
200 enrolled
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer
Phase 2 Completed
30 enrolled
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
Phase 2 Completed
40 enrolled
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase 1 Completed
75 enrolled
ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma
Phase 1/2 Completed
82 enrolled
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
Phase 1 Completed
70 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
Phase 1 Completed
30 enrolled